Gastric cancer

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1594-

  Fernández Fernández, Francisco José ^a   Sesma, Pascual ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

CANCER RISK; CARCINOGENESIS; GENOTYPE; HEALTH CARE ORGANIZATION; HELICOBACTER INFECTION; INCIDENCE; LETTER; LONG TERM CARE; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STOMACH CANCER;

COCARCINOGENESIS; HELICOBACTER INFECTIONS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 70350608450     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61947-4     Document Type: Letter

References (5)

1. Hartgrink H.H., Jansen E.P., van Grieken N.C., and van de Velde C.J. Gastric cancer. Lancet 374 (2009) 477-490
2. Kuipers E.J., Lundell L., Klinkenberg-Knol E.C., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334 (1996) 1018-1022
3. Kuipers E.J. Proton pump inhibitors and gastric neoplasia. Gut 55 (2006) 1217-1221
4. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
5. Kahrilas P.J., Shaheen N.J., and Vaezi M.F. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 135 (2008) 1392-1413